Next Article in Journal / Special Issue
Links Between Iron and Lipids: Implications in Some Major Human Diseases
Previous Article in Journal / Special Issue
Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease

Potential Treatment of Retinal Diseases with Iron Chelators

F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, Philadelphia, PA 19104, USA
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China
Author to whom correspondence should be addressed.
Pharmaceuticals 2018, 11(4), 112;
Received: 1 September 2018 / Revised: 8 October 2018 / Accepted: 10 October 2018 / Published: 22 October 2018
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
Iron is essential for life, while excess iron can be toxic. Iron generates hydroxyl radical, which is the most reactive free radical, causing oxidative stress. Since iron is absorbed through the diet but not excreted from the body, it accumulates with age in tissues, including the retina, consequently leading to age-related toxicity. This accumulation is further promoted by inflammation. Hereditary diseases such as aceruloplasminemia, Friedreich’s ataxia, pantothenate kinase-associated neurodegeneration, and posterior column ataxia with retinitis pigmentosa involve retinal degeneration associated with iron dysregulation. In addition to hereditary causes, dietary or parenteral iron supplementation has been recently reported to elevate iron levels in the retinal pigment epithelium (RPE) and promote retinal degeneration. Ocular siderosis from intraocular foreign bodies or subretinal hemorrhage can also lead to retinopathy. Evidence from mice and humans suggests that iron toxicity may contribute to age-related macular degeneration pathogenesis. Iron chelators can protect photoreceptors and RPE in various mouse models. The therapeutic potential for iron chelators is under investigation. View Full-Text
Keywords: chelation; iron; retina; age-related macular degeneration (AMD) chelation; iron; retina; age-related macular degeneration (AMD)
Show Figures

Figure 1

MDPI and ACS Style

Shu, W.; Dunaief, J.L. Potential Treatment of Retinal Diseases with Iron Chelators. Pharmaceuticals 2018, 11, 112.

AMA Style

Shu W, Dunaief JL. Potential Treatment of Retinal Diseases with Iron Chelators. Pharmaceuticals. 2018; 11(4):112.

Chicago/Turabian Style

Shu, Wanting, and Joshua L. Dunaief 2018. "Potential Treatment of Retinal Diseases with Iron Chelators" Pharmaceuticals 11, no. 4: 112.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop